FIFTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • March 23rd, 2023 • Equillium, Inc. • Pharmaceutical preparations
This Fifth Amendment to Collaboration and License Agreement (“Amendment”) is made and entered into effective as of November 18, 2022 (the “Amendment Date”), by and between Equillium, Inc., a corporation organized under the laws of the State of Delaware, USA, with its principal office at 2223 Avenida de la Playa, Suite 108, La Jolla, California 92037, USA (“Equillium”), and Biocon Limited, a company incorporated and existing under the laws of India and having its registered office at 20th KM, Hosur Road, Electronics City P.O. Bangalore 560 100, India (“Biocon”).
ASSET PURCHASE AGREEMENT between Ono Pharmaceutical Co., Ltd., and Equillium, Inc. Dated as of December 5, 2022Asset Purchase Agreement • March 23rd, 2023 • Equillium, Inc. • Pharmaceutical preparations • Delaware
This Asset Purchase Agreement (this “Agreement”) is being entered into as of December 5, 2022, by and between Ono Pharmaceutical Co., Ltd., a Japan kabushiki kaisha (“Ono”), and Equillium, Inc., a Delaware corporation (“Equillium”). Ono and Equillium are referred to herein individually as a “Party” and together as the “Parties”.
